Value Partners Group

Value Partners Group is one of Asia’s largest and most established asset management firms, with approximately US$5.1 billion in assets under management as of December 2024. The firm offers a range of investment products including equities, fixed income, alternatives, multi-assets and quantitative solutions. It was the first asset management firm listed on the Main Board of the Hong Kong Stock Exchange and has over 30 years of history[1]. While it operates several funds—including the "Value Partners Health Care Fund" which invests globally in healthcare companies—Value Partners itself does not conduct drug development or clinical research[2]. The Health Care Fund's top holdings include BeiGene Ltd., Jiangsu Hengrui Pharmaceuticals Co Ltd., Shenzhen Mindray Bio-Medical Electronics Co Ltd., Akeso Inc., Innovent Biologics Inc., among others[2]. The group employs over 50 investment professionals focused on Greater China and Asia investments. As an asset manager/investment holding company, it does not have its own pipeline or therapeutic programs.